Kajalakshmy M. (2022). Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes. Journal for ReAttach Therapy and Developmental Diversities, 5(2), 788–792. https://doi.org/10.53555/jrtdd.v5i2.3854